Tiziana Life Sciences (NASDAQ:TLSA) Stock Makes a Big Move: But Why?
Clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, Precision BioSciences along with its ARCUS genome editing platform, and Tiziana Life Sciences (NASDAQ:TLSA) announced on September 2, 2021, a specific license agreement for exploring Tiziana’sforalumab, a completely human anti-CD3 monoclonal antibody for inducing tolerance to improve the clinical outcome of CAR T cell therapy. Alan List, M.D., Chief Medical Officer at Precision BioSciences, said that the firm…